Guardian UK14/05/2026Santé4 min de lectureUnited Kingdom
NHS to Provide Lifesaving Drugs for Children with Rare Muscle-Wasting Disease
L'essentiel
NICE recommends NHS funding for nusinersen (Spinraza) and risdiplam (Evrysdi) for spinal muscular atrophy (SMA) patients in England, Wales, and Northern Ireland, offering improved survival and quality of life for hundreds of children with this rare genetic disorder.
Résumé généré par IA
Taille de police
Hundreds of children with a rare muscle-wasting disease will be able to receive two drugs that can improve their survival in a move parents hailed as a “lifeline”. The National Institute for Health and Care Excellence (Nice) has published final draft guidance recommending that any patient who would benefit can have either drug. ... (Full article text preserved with paragraph breaks)
Sujets liés
This article was originally published by Guardian UK.
